132 related articles for article (PubMed ID: 15663159)
1. Detrusor overactivity--an update.
Toozs-Hobson P; Elnaqa A
BJOG; 2004 Dec; 111 Suppl 1():53-6. PubMed ID: 15663159
[No Abstract] [Full Text] [Related]
2. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Onabotulinumtoxina.
Doggweiler R
J Urol; 2011 Jun; 185(6):2023-4. PubMed ID: 21496846
[No Abstract] [Full Text] [Related]
3. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity.
Kuo HC
Urology; 2003 Mar; 61(3):550-4. PubMed ID: 12639645
[TBL] [Abstract][Full Text] [Related]
4. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity.
Harper M; Popat RB; Dasgupta R; Fowler CJ; Dasgupta P
BJU Int; 2003 Aug; 92(3):325-6. PubMed ID: 12887493
[No Abstract] [Full Text] [Related]
5. [Drug therapy of bladder dysfunction].
Caremel R; Cornu JN; Kerdraon J; Castel-Lacanal E; Bastide C; Bruyere F; Guy L; Karsenty G
Prog Urol; 2013 Nov; 23(15):1271-86. PubMed ID: 24183086
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
Alvares RA; Silva JA; Barboza AL; Monteiro RT
Int Braz J Urol; 2010; 36(6):732-7. PubMed ID: 21176280
[TBL] [Abstract][Full Text] [Related]
7. Botulinum injection is useless on fibrotic neuropathic bladders.
Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin in multiple sclerosis.
Jost WH
J Neurol; 2006 Feb; 253 Suppl 1():I16-20. PubMed ID: 16477480
[TBL] [Abstract][Full Text] [Related]
9. Overactive Bladder.
White N; Iglesia CB
Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
[TBL] [Abstract][Full Text] [Related]
10. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
Kuo HC
Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA Injections for Urge Incontinence.
Hubb AJ; Stachowicz AM; Wood SC
Am Fam Physician; 2018 Feb; 97(3):Online. PubMed ID: 29431973
[No Abstract] [Full Text] [Related]
13. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
14. Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity.
Joussain C; Phé V; Even A; Chartier-Kastler E; Denys P
Eur J Phys Rehabil Med; 2017 Dec; 53(6):991-997. PubMed ID: 29072045
[TBL] [Abstract][Full Text] [Related]
15. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
Ghalayini IF; Al-Ghazo MA
Neurourol Urodyn; 2007; 26(4):531-536. PubMed ID: 17330289
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A for the treatment of lower urinary tract disorders.
Yokoyama T; Chancellor MB; Oguma K; Yamamoto Y; Suzuki T; Kumon H; Nagai A
Int J Urol; 2012 Mar; 19(3):202-15. PubMed ID: 22220916
[TBL] [Abstract][Full Text] [Related]
17. Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era.
Prakash NS; Lopategui DM; Gomez C
Curr Urol Rep; 2017 Aug; 18(8):64. PubMed ID: 28689244
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
[TBL] [Abstract][Full Text] [Related]
19. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Harris MA; Harding C; Fulford S; Whiteway J
BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
[No Abstract] [Full Text] [Related]
20. Clinical management of spasticity.
Thompson AJ; Jarrett L; Lockley L; Marsden J; Stevenson VL
J Neurol Neurosurg Psychiatry; 2005 Apr; 76(4):459-63. PubMed ID: 15774425
[No Abstract] [Full Text] [Related]
[Next] [New Search]
